PLRZ logo

POLYRIZON LTD

PLRZNASDAQ
🏆 #4731 by market capUS Equity
$11.03▲ $0.36 (+3.23%)
After hours · at close
🔔
Track PLRZ
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 3.2%
7d▼ 0.1%
14d▲ 0.1%
30d▼ 13.2%
ytd▲ 35.9%
1y▲ 60.5%
🏦Market Cap
$23M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
60
Fair

Trading Snapshot

Day Range
$10.95 – $11.18
52-Week Range
$2.88 – $18.20
Volume
$4.24B
Avg Volume
$4.93B
Shares Outstanding
2.1M
Next Earnings
Oct 21, 2026

Fundamentals Snapshot

Annual Revenue
$5M
Last Q Revenue
$1M
P/E Ratio
—
P/S Ratio
—
EPS (TTM)
$-5.64
Dividend Yield
—
Dilution (1yr)
+11801.6%

Why Investors Own PLRZ

  • ✓High-growth profile — revenue up +27.7% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 62% gross margin and 28% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

PLRZ logo

POLYRIZON LTD

PLRZ
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$6M▲ +380.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$5M▲ +295.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
1.6M▲ +11801.6% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$1M▼ −$1M YoY
StockOtter · stockotter.space

About POLYRIZON LTD

Polyrizon Ltd. is an Israeli biotechnology firm specializing in the creation of medical device hydrogels, delivered as nasal sprays. These innovative sprays are designed to form a protective barrier within the nasal cavity, preventing viruses and allergens from attaching to the nasal epithelial tissue. Its current development pipeline features several targeted solutions, including PL-14, formulated to block nasal allergies; PL-15, aimed at combating COVID-19; and PL-16, for influenza prevention. Established in 2005, the company operates from its headquarters in Ra'anana, Israel.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
60/100

Analyst Price Target

ⓘ
Average Target
$13.63
▲ +23.6% Upside
High Target$15.35
Low Target$12.69
Based on 13 analysts

Latest News & Updates

🚀
MarketWatch·2h ago

POLYRIZON LTD tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Bloomberg·5h ago

Analysts lift PLRZ price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Barron’s·1d ago

POLYRIZON LTD announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.